Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SEP-363856 versus placebo in acutely psychotic adults with schizophrenia
2019-000470-36Phase 3Terminated
- Sponsor
- Sunovion
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (3 arms), sponsored by Sunovion. Primary endpoint: Change from baseline in PANSS total score at endpoint. Started Jul 2019; status: terminated.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2019-000470-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000470-36.